Genetix Pharmaceuticals, a Cambridge, MA- and Paris, France-based gene therapy company developing innovative treatments for severe genetic disorders, has completed a $35m Series B financing.
Participants in the round include new investors Third Rock Ventures and Genzyme Ventures, which joined TVM Capital, Forbion and Easton Capital.
Genetix Pharmaceuticals’ products treat the underlying cause of genetically based diseases by delivering corrective genes to the patient’s own bone marrow, providing the potential for a one-time transformative treatment
The new capital will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
The company is led by an experienced team with a proven track record of building successful life sciences companies.
The new members of the management team include:
– Nick Leschly from Third Rock Ventures as Interim President;
– Mitchell Finer, Ph.D. as Chief Scientific Officer;
– Phil Reilly, M.D. from Third Rock Ventures as Interim Chief Medical Officer;
– Anup Arora from Easton Capital, who is continuing to lead the business development and operations activities on an interim basis.
Following the financing, the new board of directors will consist of Jim Geraghty of Genzyme; Axel Polack, M.D. of TVM Capital; Geert-Jan Mulder, M.D. of Forbion and Nick Leschly of Third Rock Ventures.